E. Hanze

Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors

A. S. Krishnatry, G. Ferron-Brady, M. Prohn, 2021, CPT: pharmacometrics & systems pharmacology.

Allopregnanolone Concentrations in Breast Milk and Plasma from Healthy Volunteers Receiving Brexanolone Injection, With Population Pharmacokinetic Modeling of Potential Relative Infant Dose

A. Henningsson, E. Hoffmann, K. Deligiannidis, 2022, Clinical Pharmacokinetics.

Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC‐0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor

L. Chinn, H. Winter, A. Serone, 2018, Clinical pharmacology and therapeutics.

Population pharmacokinetics and exposure–response of anti‐programmed cell death protein‐1 monoclonal antibody dostarlimab in advanced solid tumours

S. Visser, Sharon M. Lu, Y. Gandhi, 2022, British journal of clinical pharmacology.

Population Pharmacokinetics of Nifurtimox in Adult and Pediatric Patients With Chagas Disease

H. Stass, S. Willmann, I. Ince, 2022, Journal of clinical pharmacology.

Sarecycline treatment for acne vulgaris: Rationale for weight‐based dosing and limited impact of food intake on clinical efficacy

A. Grada, E. Graber, A. Moore, 2021, Dermatologic therapy.

Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Age‐Related Macular Degeneration

M. Kågedal, M. Maia, T. Lu, 2023, Journal of clinical pharmacology.

Semiparametric Distributions With Estimated Shape Parameters

Mats O. Karlsson, Radojka M. Savic, Klas J. F. Petersson, 2009, Pharmaceutical Research.